Sequential Moxifloxacin Administration in the Treatment of Community Acquired Pneumonia
Abstract
Objective To survey the safety and clinical therapeutic effectiveness of sequential moxifloxacin administration in the treatment of community acquired pneumonia(CAP). Methods Ninety-four cases of CAP were randomly divided into 2 equal groups: the treatment group and control group.Patients in the treatment group were given each 400 mg of moxifloxacin injection administered by intravenous instillation q.d.for 5 consecutive days,followed by 400 mg of moxifloxacin tablets PO,q.d.for 9 consecutive days.Patients in the control group were given each 1.5 g of cefuroxime sodium injection administered by intravenous injection,t.i.d.for 5 consecutive days,followed by 500 mg of cefuroxime sodium tablets PO,b.i.d.for 9 consecutive days.The full course of treatment in both groups lasted 14 days. Results The overall effective rates in patients treated with moxifloxacin and cefuroxiume sodium were 93.6% and 78.7%,respectively(P0.05).The total bacteria elimination rates in patients treated with moxifloxacin and cefuroxiume sodium were 91.3% amd 86.4%,respectively(P0.05). Conclusion The sequential moxifloxacin medication is safe,effective and handy in the treatment of patients with community acquired pneumonia.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.